Products / Trail Range Livestock / Electrolyte Advanced

RangeStart · Bovine

Electrolyte Advanced

An oral electrolyte concept for the scouring or dehydrated calf. Four variables govern it and cannot be optimised independently — osmolality, sodium concentration, alkalinising capacity and energy — because the last three act through osmolality on abomasal emptying, and therefore on how fast sodium reaches the small intestine.

Livestock healthBovine
59 g single-dose sachet — makes 2 litres · 5 lb (2.27 kg) tub — 38 doses, proposed
Crude protein
11.0%minimum, as fed
Crude fat
0.0%minimum, as fed
  • Sodium 125 mmol/L in the prepared solution
  • Single-dose sachet — one sachet makes 2 litres, no scoop and no arithmetic
  • Acetate at 123 mmol/L — chosen, not maximised
  • Glucose and glycine together for sodium co-transport
  • Osmolality 409 mOsm/L, counting every ingredient

Statements of fact about the formula. None is a health claim.

Online ordering opens once distribution is in place. Wholesale and trade enquiries are open now.

Brand
Trail Range
Family
RangeStart
Category
Livestock health
Species
Bovine
Commercial status
In development — not offered for sale
Internal SKU
RSTR-ELA-SAC · RSTR-ELA-05LB
Retail UPC
GS1 assignment pending — one per pack size

Guarantee against formulation

What the label promises, and what the formula delivers

A guarantee is a floor, not a target. The distance between the two is the margin a production run can move within before the label stops being true, and a control fails the build if any formulation ever sits below its own guarantee.

  • Crude Protein

    +0.9 pts11.0% guaranteed · 11.9% delivered

  • Crude Fat

    +0.0 pts0.0% guaranteed · 0.0% delivered

Guaranteed minimum — 11.0% protein, 0.0% fatFormulation delivers — 11.9% protein, 0.0% fatThe guarantee line

The detail

Everything on the panel

Development targets from the working formulation. A guaranteed analysis is derived from assay of finished production batches, and none has been made — so these are the values the formula is built to, not results.

Crude Proteinmin.11.0%
Crude Fatmin.0.0%
Crude Fibermax.0.5%
Moisturemax.5.0%
Sodiummin.2,875 mg/litre (125 mmol/L)
Potassiummin.978 mg/litre (25 mmol/L)
Chloridemin.959 mg/litre (27 mmol/L)

Two bases, deliberately. The proximate guarantees are per the powder as sold; the electrolytes are per litre of prepared solution, because the litre is the unit anyone handles at the calf. The proximates previously read 0.4% protein — that figure was per litre of the LIQUID this product used to be, and it did not survive the change to a powder. Crude protein here is glycine: Kjeldahl counts a free amino acid as protein.

Serving size

One sachet (59 g) in 2 litres — approx. 116 kcal

Energy

Approximately 116 kcal per prepared 2-litre dose

Calculated by the modified Atwater method. Measured values typically run 5–9% higher on dry food, so this is restated once batch data exists.

Nutritional adequacy

Intended for intermittent or supplemental feeding only.

A treat labelled for intermittent or supplemental feeding carries no adequacy statement, because it is not offered as a complete diet.

The panel itself

Read the label, not a description of it

The artwork that goes on the pack, beside the guarantee it carries.

Why this band exists

A buyer comparing two bags is reading label panels. Showing ours at full size, beside the same figures in the table above, is a claim that cannot be made cheaply: it requires the artwork and the specification to already agree.

Where the artwork does not exist yet the band still builds, with a marked placeholder holding the space — so the page keeps one shape across the range and a missing panel reads as pending rather than as a design that broke.

Market role

Nutrition & Performance for Livestock Production

Trail Range Livestock provides the broader livestock architecture. FirstLight is the endorsed neonatal brand within the RangeStart early-life line, focused on colostrum development.

FarmsRanchesLivestock professionalsAgricultural distributors

Line-level context, shown here because it answers “what is this for” at the moment someone is looking at one product. The line page carries it in full.

Formulation direction

What the evidence supports — and what it does not.

Development inputs, not finished formulas. Each candidate is graded on the published evidence, including the ingredients the evidence tells us to leave out.

Colostrum programs and neonatal nutrition

Establishing passive immunity in the first 24 hours, when gut closure limits the absorption window.

Lead with

  • IgG source and absorption efficiency, not IgG mass alone

    Established

    The decisive formulation insight in this category. Apparent efficiency of absorption measured 38.8% for a colostrum-derived product against 21.6% for a plasma-derived one, producing very different passive-transfer rates from comparable IgG mass. Source selection outranks dose.

    Basis2013Controlled study2007Controlled study

  • Clinoptilolite in the first-24-hour colostrum window, at low inclusion

    Emerging

    One controlled trial (n=60) found higher serum IgG and higher apparent efficiency of absorption when a clinoptilolite suspension accompanied colostrum; a second (n=18) found γ-globulin — a proxy measure, not IgG directly — above control at 0.5%. Both point to enhancement rather than interference, and both come from closely related research groups, with the window set by gut closure. Critically dose-dependent: roughly 0.5% of the meal outperformed 2%, and higher intakes turn the effect the other way. Tolerance at up to 2% of milk replacer over 28 days is separately documented. Specify clinoptilolite by name and CAS number: chabazite, phillipsite and synthetic zeolite A are different materials with different behaviour and no transferable evidence.

    Basis2008Controlled study2018Controlled study2008Controlled study

  • Oral electrolyte formulation for rehydration

    Moderate

    Oral electrolyte solution outperformed intravenous and subcutaneous routes for restoring plasma volume and correcting blood pH in calves retaining gut function. Sodium content, alkalinising capacity, energy source and osmolality are the formulation variables.

    Basis2019Controlled study

Deprioritise or exclude

  • Inherited category performance data

    Counter-indicated

    Performance is product-specific. One marketed replacer achieved adequate passive transfer in 6.9% of calves against 72% on maternal colostrum. No product may borrow another's result, and the disease-risk epidemiology attached to failure of passive transfer is associational, not a measured product effect.

    Basis2016Systematic review2007Controlled study

Claim ceiling. Composition only until licensed. Marketing a product as treating failure of passive transfer requires a USDA veterinary biologic licence; immune and immunoglobulin claims fall under biologics licensing, not feed registration. A numeric designation may denote verified IgG per dose but must never imply achieved serum IgG.

Substantiation required. Product-specific passive-transfer verification against an untreated arm, analytical IgG method and lot consistency, and — for any replacer or immunity positioning — the licensing pathway rather than feed registration.

Every brief covering RangeStart is shown rather than only those bearing on this product, because a brief is a development input for a category and not a statement about one item. Narrowing it further needs a per-product category on the record.

Evidence map

The sources this product answers to — with their limits visible.

These sources guide standards, ingredient review and study design. They do not automatically substantiate an unfinished product.

11 sources · 2026 back to 2007

2026 · Regulatory guidance

9 CFR Part 102 — licensing of veterinary biological products

USDA APHIS (Virus-Serum-Toxin Act, via eCFR)

Scope. Establishment and product licence requirements, and the data establishing purity, safety, potency and efficacy that an application must include.

Supports. Defines the pathway for any product presented as acting on immunity, and requires that all claims intended for labels and advertising be submitted as part of the application.

Does not establish. Does not apply to products marketed purely on nutrient contribution; conversely, no feed registration substitutes for a biologic licence where an immunity claim is made.

Primary source ↗

2020 · Consensus recommendations

Consensus recommendations on calf- and herd-level passive immunity in dairy calves in the United States

Journal of Dairy Science

Scope. Replaces the binary pass/fail passive-transfer standard with four serum IgG categories and corresponding herd-level distribution goals.

Supports. The current US reference framework against which a colostrum program and any product used within it should be benchmarked and monitored.

Does not establish. Does not establish that any product or protocol moves calves between categories; it defines measurement thresholds and herd targets, not interventions.

Primary source ↗

2019 · Controlled study

Comparison of oral, intravenous and subcutaneous fluid therapy for resuscitation of calves with diarrhea

Journal of Dairy Science

Scope. Randomised trial in calves with induced diarrhoea and dehydration comparing oral electrolyte solution against intravenous and subcutaneous routes.

Supports. Substantiates a properly formulated oral electrolyte as first-line rehydration for calves that retain a functional gut.

Does not establish. Does not reflect naturally occurring disease — diarrhoea was experimentally induced, acidemia was relatively mild, and treatment arms were not composition-matched.

Primary source ↗

2018 · Controlled study

Serum protein electrophoretic pattern in neonatal calves treated with clinoptilolite

Molecules

Scope. 18 calves in three groups — colostrum alone, colostrum plus 0.5% clinoptilolite, colostrum plus 2% — dosed within two hours of birth and again at 12 and 24 hours.

Supports. The only head-to-head dose comparison in the colostrum window: at 30 hours the 0.5% group showed γ-globulin markedly above control, and the authors conclude the lower dose was the more effective of the two.

Does not establish. Does not measure IgG directly (γ-globulin is a proxy), uses six calves per arm, records no clinical endpoint, and shows the higher 2% dose performing worse than 0.5% — the effect is dose-critical, not linear.

Primary source ↗

2016 · Systematic review

Failure of passive immune transfer in calves: a meta-analysis on the consequences and assessment of the economic impact

PLOS ONE

Scope. Meta-analysis of 68 published models quantifying adjusted risk of mortality, respiratory disease, diarrhoea and overall morbidity associated with failure of passive transfer.

Supports. Quantifies the health burden attached to failure of passive transfer, justifying it as a high-value development target.

Does not establish. Does not demonstrate that raising serum IgG by any given intervention delivers a proportional reduction in disease — the estimates are associational, with substantial heterogeneity.

Primary source ↗

2016 · Systematic review

Diagnostic accuracy of refractometry for assessing bovine colostrum quality: a systematic review and meta-analysis

Journal of Dairy Science

Scope. Meta-analysis of 11 studies and 4,251 colostrum samples evaluating Brix refractometry against an IgG standard at different cutoffs.

Supports. Validates on-farm Brix as a screening input for colostrum quality decisions and quantifies the confidence each cutoff carries.

Does not establish. Does not establish that Brix predicts a calf's achieved serum IgG — it measures agreement with colostral IgG concentration only.

Primary source ↗

2016 · Systematic review

Invited review: transitioning from milk to solid feed in dairy heifers

Journal of Dairy Science

Scope. Review of rumen ecosystem development, fermentation, papillae growth and rumination behaviour across the milk-to-solid-feed transition.

Supports. Informs starter formulation direction — specifically the balance between physically effective fibre and readily degradable carbohydrate.

Does not establish. Does not provide a validated numeric formulation specification, and as a narrative review applies no systematic risk-of-bias appraisal.

Primary source ↗

2013 · Controlled study

Effect of feeding maternal colostrum or plasma-derived or colostrum-derived colostrum replacer on passive transfer, health and performance of preweaning heifer calves

Journal of Dairy Science

Scope. Three-arm trial comparing maternal colostrum against plasma-derived and colostrum-derived replacers, measuring apparent efficiency of absorption and passive-transfer adequacy.

Supports. Establishes that IgG source and absorption efficiency — not IgG mass alone — drive achieved serum IgG, a core formulation consideration.

Does not establish. Does not establish an upper bound on replacer performance, as it tested a single dose of each replacer rather than dose-matched IgG.

Primary source ↗

2008 · Controlled study

Apparent efficiency of immunoglobulin absorption in newborn calves orally treated with zeolite

Acta Veterinaria

Scope. 60 Holstein calves in four groups, fed colostrum at two volumes with or without a 25% clinoptilolite suspension, measuring serum IgG and apparent efficiency of absorption.

Supports. The largest trial addressing clinoptilolite and colostral immunoglobulin directly: serum IgG at six hours was significantly higher with zeolite at the lower colostrum volume, and apparent efficiency of absorption was highest in that group — the mineral enhanced rather than impaired absorption.

Does not establish. Does not establish a mechanism, was not blinded, records no clinical outcomes such as morbidity or scours, and comes from a single research group.

Primary source ↗

2008 · Controlled study

Clinical observations, biochemical data and postmortem findings in young dairy calves fed zeolite clinoptilolite with milk replacer

American Journal of Veterinary Research

Scope. 26 Holstein calves fed milk replacer with 0%, 0.5% or 2% clinoptilolite twice daily for 28 days, all necropsied.

Supports. The best tolerance dataset in neonatal calves — no gross lesions attributable to treatment at necropsy, and no adverse haematology or biochemistry.

Does not establish. Does not show any benefit; it was designed as a safety study, found no difference in bodyweight or average daily gain, and reported an unexplained increase in jejunal mucosal eosinophils in treated calves.

Primary source ↗

2007 · Controlled study

Passive transfer of immunoglobulin G and preweaning health in Holstein calves fed a commercial colostrum replacer

Journal of Dairy Science

Scope. Trial comparing maternal colostrum against a commercial colostrum replacer regimen, measuring 24-hour serum IgG and passive-transfer adequacy.

Supports. Demonstrates directly that a marketed colostrum replacer can fail to deliver adequate passive transfer, establishing why product-specific validation is mandatory.

Does not establish. Does not generalise to all replacers — the result characterises one product and dosing regimen, not the category.

Primary source ↗

Rest of the line

RangeStart

Documentation

What a buyer can ask for

Three documents, and the state each is actually in. A buyer asking “what can you send me?” wants the answer as a list of things they can request, not as a status band they have to interpret.

Available now

Specification packet

Formulation, guarantees, the acceptance windows each is judged against and the regulatory edition in force, with a revision hash so two copies can be told apart.

Available now

Claim sheet

Every claim the label makes, the basis for each one, and — the part buyers rarely get — the terms we have deliberately not used, with the reason.

On manufacture

Certificate of analysis

Per lot, assayed against the acceptance windows above. Available once a production run exists — which is also when the guaranteed analysis stops being a target and becomes a result.

Documentation statusSpecified

Formulation, guaranteed analysis, ingredient statement and label copy are documented, and the figures are checked against each other automatically rather than by proofreading.

Documented

  • Formulation recorded, and every guarantee is checked against what the formula actually delivers — a minimum above the formulation value cannot hold on assay.
  • Ingredient statement written in descending order by weight using AAFCO ingredient names.
  • Guaranteed analysis specified.
  • Serving size, pack sizes and feeding directions specified.
  • Print-ready panel copy written — front panel, ingredient statement, guaranteed analysis and directions, section 23 of the label copy deck.
  • Internal SKU assigned, one per saleable pack.

Not yet established

  • No production batch has been made. A guaranteed analysis is derived from assay of finished batches — mean − 2 SD for minima, mean + 2 SD for maxima — so every figure shown is the value the formula is built to, not a verified result.
  • Retail GTIN-12 pending. A UPC must be licensed from GS1 under the registered brand owner; internal SKUs are not substitutes and are not scannable.
  • Supplied packaging artwork is concept art. Names, claims, formats and sizes shown on an image are not approved product facts.

Claim ceiling: Oral rehydration of the diarrhoeic calf is a therapeutic use and diarrhoea is a disease, which places any treatment or recovery language outside what a feed may say. “Recovery” is the single most dangerous word available in this category. What may be stated is composition: ion concentrations per litre of prepared solution, which is what a veterinarian comparing two products actually reads.